JPH11510793A - 胃腸病に対する鼻腔内ワクチン接種 - Google Patents

胃腸病に対する鼻腔内ワクチン接種

Info

Publication number
JPH11510793A
JPH11510793A JP9505849A JP50584997A JPH11510793A JP H11510793 A JPH11510793 A JP H11510793A JP 9505849 A JP9505849 A JP 9505849A JP 50584997 A JP50584997 A JP 50584997A JP H11510793 A JPH11510793 A JP H11510793A
Authority
JP
Japan
Prior art keywords
toxin
composition
difficile
antigen
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9505849A
Other languages
English (en)
Japanese (ja)
Inventor
ウイリアム ディー．ジュニア． トーマス
トーマス ピー． モナス
フランシスコ トレス−ロペス
ゼンクシ ザング
ウェンデ レイ
デビッド エム． ライアリー
ジェイムズ エス． モンクリーフ
Original Assignee
オラバックス インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オラバックス インク． filed Critical オラバックス インク．
Publication of JPH11510793A publication Critical patent/JPH11510793A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP9505849A 1995-07-07 1996-06-26 胃腸病に対する鼻腔内ワクチン接種 Pending JPH11510793A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49922995A 1995-07-07 1995-07-07
US08/499,229 1995-07-07
PCT/US1996/010987 WO1997002835A1 (en) 1995-07-07 1996-06-26 Intranasal vaccination against gastrointestinal disease

Publications (1)

Publication Number Publication Date
JPH11510793A true JPH11510793A (ja) 1999-09-21

Family

ID=23984386

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9505849A Pending JPH11510793A (ja) 1995-07-07 1996-06-26 胃腸病に対する鼻腔内ワクチン接種

Country Status (8)

Country Link
EP (1) EP0877623A1 (enExample)
JP (1) JPH11510793A (enExample)
CN (1) CN1195993A (enExample)
AU (1) AU722653B2 (enExample)
CA (1) CA2226392A1 (enExample)
NZ (1) NZ312876A (enExample)
WO (1) WO1997002835A1 (enExample)
ZA (1) ZA965737B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003513106A (ja) * 1999-11-01 2003-04-08 ムコバックス・ビー・ブイ 家畜における乳腺分泌抗体の生産
WO2008146830A1 (ja) * 2007-05-28 2008-12-04 The Kitasato Institute パラ百日咳菌全菌体ワクチン組成物
JP2010539172A (ja) * 2007-09-14 2010-12-16 サノフィ パスツール バイオロジクス カンパニー クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物
JP2012510497A (ja) * 2008-12-03 2012-05-10 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング ワクチンの生産方法
JP2013512916A (ja) * 2009-12-02 2013-04-18 タフツ ユニバーシティー 免疫原としてのＣｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅの無毒の組換えホロトキシン

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
US6974573B2 (en) 1999-11-01 2005-12-13 Mucovax Holdings, B.V. Antibody production in farm animals
US7074454B1 (en) 1999-11-01 2006-07-11 Mucovax Holding B.V. Production of mammary secretion antibodies in farm animals
GB0029919D0 (en) * 2000-12-07 2001-01-24 Chiron Spa Helicobacter pylori prime & boost vaccination
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
WO2013071409A1 (en) 2011-11-18 2013-05-23 National Research Council Of Canada (Nrc) Clostridium difficile lipoteichoic acid and uses thereof
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141970A (en) * 1975-05-07 1979-02-27 Internationale Octrooimaatschappij "Octropa" B.V. Method for enhancing the resistance of new born mammalian young to gastro-intestinal infections
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US4944942A (en) * 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
GB9209118D0 (en) * 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
AU4773293A (en) * 1992-07-16 1994-02-14 Oxford University Multiple particulate antigen delivery system

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003513106A (ja) * 1999-11-01 2003-04-08 ムコバックス・ビー・ブイ 家畜における乳腺分泌抗体の生産
WO2008146830A1 (ja) * 2007-05-28 2008-12-04 The Kitasato Institute パラ百日咳菌全菌体ワクチン組成物
US8465754B2 (en) 2007-05-28 2013-06-18 Kitasato Daiichi Sankyo Vaccine Co., Ltd. Bordetella parapertussis whole-cell vaccine composition
JP5398527B2 (ja) * 2007-05-28 2014-01-29 北里第一三共ワクチン株式会社 パラ百日咳菌全菌体ワクチン組成物
JP2010539172A (ja) * 2007-09-14 2010-12-16 サノフィ パスツール バイオロジクス カンパニー クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物
JP2014055174A (ja) * 2007-09-14 2014-03-27 Sanofi Pasteur Biologics Co クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物
JP2017052773A (ja) * 2007-09-14 2017-03-16 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物
US9687541B2 (en) 2007-09-14 2017-06-27 Sanofi Pastuer Biologies, LLC Pharmaceutical compositions containing Clostridium difficile toxoids A and B
US10639362B2 (en) 2007-09-14 2020-05-05 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing Clostridium difficile toxoids A and B
JP2012510497A (ja) * 2008-12-03 2012-05-10 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング ワクチンの生産方法
JP2013512916A (ja) * 2009-12-02 2013-04-18 タフツ ユニバーシティー 免疫原としてのＣｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅの無毒の組換えホロトキシン

Also Published As

Publication number Publication date
NZ312876A (en) 2000-06-23
ZA965737B (en) 1997-05-13
AU6479996A (en) 1997-02-10
CA2226392A1 (en) 1997-01-30
CN1195993A (zh) 1998-10-14
AU722653B2 (en) 2000-08-10
WO1997002835A1 (en) 1997-01-30
EP0877623A4 (enExample) 1998-11-18
EP0877623A1 (en) 1998-11-18

Similar Documents

Publication Publication Date Title
FI120137B (fi) Mutanttienterotoksiini, joka on tehokas ei-toksisena suun kautta annettavana adjuvanttina
Medaglini et al. Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization.
EP0590138A1 (en) Oral treatment of helicobacter infection
EP0771214B1 (en) Treatment and prevention of helicobacter infection
JP2002541808A (ja) ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
EP1899366A2 (en) Genes of an otitis media isolate of nontypeable haemophilus influenzae
US5919463A (en) Clostridium difficle toxins as mucosal adjuvants
AU722653B2 (en) Intranasal vaccination against gastrointestinal disease
EP0837692B1 (en) Clostridium difficile toxins and toxoids as mucosal adjuvants
JP2009173667A (ja) 病原菌のｔｉｒ遺伝子によってコードされる、病原菌の宿主の膜受容体、ｈｐ９０
EP0909272B1 (en) Helicobacter pylori adhesin binding group antigen
CA2353048C (en) Pharmaceutical composition useful in the prevention or treatment of peptic ulcers
JP2002510970A (ja) クラミジア・ニューモニエ由来の表面露出タンパク質
KR20010088302A (ko) 헬리코박터 감염에 대한 비경구 면역화 방법에 있어서의ｌｔ 및 ｃｔ
EP1368379A2 (en) Antibodies for preventing and treating attaching and effacing escherichia coli (aeec) associated diseases
AU2002242531A1 (en) Antibodies for preventing and treating attaching and effacing escherichia coli (AEEC) associated diseases
JPH11504206A (ja) 防御用ヘリコバクター抗原
US6036953A (en) Heterologous antigens in live cell V. cholerae strains
WO2013091260A1 (zh) 龋齿疫苗及制备方法
WO1998023763A9 (en) Heterologous antigens in live cell v. cholerae strains
HUT77574A (hu) Eljárás fokozott antigénaktivitású Helicobacter sp. és azt tartalmazó vakcina előállítására
HUT77876A (hu) Eljárás fokozott antigénaktivitású bélbaktériumok és azokat tartalmazó vakcinák előállítására
US7049423B2 (en) Use of the RTX secretion system to achieve heterologous polypeptide secretion by Vibrio cholerae
WO2002079240A2 (en) Intimins for the prevention or treatment of infections: i
AU675938C (en) Oral treatment of helicobacter infection